Trial reportAmerican journal of preventive medicine2026
Implementing Care for Cannabis and Other Drug Use in Adult Primary Care: Outcomes of a Cluster-Randomized Implementation Trial.
Trial report in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe U.S. Preventive Services Task Force recommends substance use screening for adults when accurate diagnosis and follow-up treatment can be offered. This study evaluated whether implementation of population-based screening and symptom assessment increased treatment for cannabis and other drug use disorders in a large primary care system.
methodsNineteen randomized regional healthcare system sites implemented population-based screening and symptom assessment for cannabis and other drug use as part of a stepped-wedge trial to integrate mental health in adult primary care from January 2016 to July 2018. Implementation strategies included practice facilitation, electronic health record decision support, and performance feedback. Outcomes included treatment initiation and engagement rates among patients with any new drug use disorder and, secondarily, the rates for specific drug use disorders (e.g., cannabis use disorder), using electronic health record and insurance claims data. Mixed-effect logistic regression modeled binary outcomes before and after implementation (January 2015-January 2019), adjusted for randomization stratification and time, accounting for person-level repeated outcomes. Monthly outcome rates (per 10,000 patient-visits) were estimated using marginal standardization. Analyses were conducted in 2023-2024.
resultsBefore implementation, 244,542 patients had 942,400 visits; after implementation, 287,696 patients had 1,087,565 visits. Implementation resulted in an increased cannabis screening (9-153 per 10,000 patient-visits; p<0.001) and newly identified cannabis use disorder (10-17 per 10,000 patient-visits; p<0.001). Treatment initiation for cannabis use disorder increased by 0.5-1 per 10,000 patient-visits (p=0.006), but treatment engagement did not change (p=0.147). Treatment initiation and engagement for any drug use disorder did not change (p=0.777 and 0.584).
conclusionsFindings underscore the potential value of integrating population-based cannabis screening/assessment in primary care for treatment initiation and highlight the need for improved engagement for cannabis use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.